Skip to main content
MDLNMedline Inc.Sell5.6·$38.75+2.98%
SellModerate Confidence
Investment thesis

Medline enters the analysis with 23% upside to the analyst price target and a 3.3-to-1 favorable risk/reward — supported by consecutive earnings beats and a near-perfect Piotroski financial-health score — but heavy reliance on three group-purchasing organizations for approximately 69% of revenues remains the central concentration risk.

Thesis pillars

  • Gpo Customer Concentration RiskDeteriorating
  • Material Upside Favorable Risk RewardStable
  • Early Earnings Beat ConsistencyDeteriorating
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Medline Inc. (MDLN) Stock Analysis

SellVALUE-TRAP 1/5GrowthModerate Confidence

Healthcare · Medical Instruments & Supplies

Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $38.75 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%); Negative news sentiment (-0.67).

Medline, founded in 1966, is the largest provider of med-surg products by total net sales, distributing approximately 335,000 products through Medline Brand and Supply Chain Solutions segments to hospitals, surgery centers, physician offices, and post-acute facilities globally.... Read more

$38.75+18.3% A.UpsideScore 5.6/10#17 of 32 Medical Instruments & Supplies
QualityF-score8 / 9FCF yield
Stop $36.04Target $45.83(analyst − 10%)A.R:R 2.1:1
Analyst target$50.92+31.4%26 analysts
$45.83our TP
$38.75price
$50.92mean
$62

Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $38.75 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%); Negative news sentiment (-0.67). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.

Passes 4/8 gates (favorable risk/reward ratio, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity and news soft fda negative. Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-26
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Aug 5, 202611d to earnings· next earnings call

Thesis

Rewards
Strong growth profile
Risks
Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%)
Negative news sentiment (-0.67)
Negative momentum

Key Metrics

P/E (TTM)32.8
P/E (Fwd)23.3
Mkt Cap$69.0B
EV/EBITDA16.8
Profit Mgn3.3%
ROE6.1%
Rev Growth10.7%
Beta
DividendNone
Rating analysts35

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C2.80bearish
IV64%elevated

Concentration Risks(10-K Item 1A)

  • HIGHCustomerVizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs)69%
    10-K Item 1A: 'approximately $19.7 billion (or 69% of consolidated net sales ... contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.'
  • LOWCustomertop five U.S. customers11%
    10-K Item 1A: 'our top five U.S. customers represented approximately $3.2 billion (or 11.3%) of our net sales'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
1.3
Rsi
3.5
Ma Position
4.5
Obv
10.0
Volume accumulation (rising OBV)
GatesMomentum 3.9<4.5INSIDER 5.21%=EXTREMENEWS SOFT FDA NEGATIVEEARNINGS PROXIMITY 11d<=14d (soft)A.R:R 2.1 ≥ 1.5No SEC red flagsSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
36 · Neutral
20D MA 50D MA 200D MASupport $36.60Resistance $43.63

Price Targets

$36
$46
A.Upside+18.3%
A.R:R2.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! momentum at 3.9 (below the engine's 4.5 threshold)
! Insider activity: 5.21%=extreme
! NEWS_SOFT:FDA_NEGATIVE

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-05 (11d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is MDLN stock a buy right now?

Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $38.75 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%); Negative news sentiment (-0.67). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $36.04. Score 5.6/10, moderate confidence.

What is the MDLN stock price target?

Take-profit target: $45.83 (+18.3% upside). Prior stop was $36.04. Stop-loss: $36.04.

What are the risks of investing in MDLN?

Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%); Negative news sentiment (-0.67); Negative momentum.

Is MDLN overvalued or undervalued?

Medline Inc. trades at a P/E of 32.8 (forward 23.3). TrendMatrix value score: 6.5/10. Verdict: Sell.

What do analysts say about MDLN?

35 analysts cover MDLN with a consensus score of 4.1/5. Average price target: $51.

What does Medline Inc. do?Medline, founded in 1966, is the largest provider of med-surg products by total net sales, distributing approximately...

Medline, founded in 1966, is the largest provider of med-surg products by total net sales, distributing approximately 335,000 products through Medline Brand and Supply Chain Solutions segments to hospitals, surgery centers, physician offices, and post-acute facilities globally. Prime Vendor agreements generated $18.0 billion (63.4% of net sales) in 2025; the company operates 70 global distribution centers and 2,100+ owned MedTrans trucks, employing over 45,000 people.

Related stocks: WST (West Pharmaceutical Services, I) · RMD (ResMed Inc.) · ISRG (Intuitive Surgical, Inc.) · ALGN (Align Technology, Inc.) · RGEN (Repligen Corporation)
Home Stocks MDLN

Latest news

Latest News

Benzinga3d agoCONCERNFda Decision
Investing.com South Africa73d agoAnalyst
MarketBeat80d ago
ACCESS Newswire81d agoLegal
Quiver Quantitative81d agoEarnings
Insider Monkey81d agoProduct
MarketBeat81d ago
Investing.com India81d ago
Quiver Quantitative81d agoEarnings
Kare11.com81d agoEarnings
MarketBeat89d ago
Meyka82d agoEarnings
MarketBeat87d ago
MSN87d agoFda Decision
Meyka79d ago
MSN80d agoEarnings
MarketBeat80d agoAnalyst
MarketBeat80d agoAnalyst
Investing.com South Africa80d ago
Insider Monkey91d agoProduct
Loading more...